Galena in-license of Zuplenz makes sense, says Piper Jaffray Piper Jaffray believes Galena's decision to in-license Zuplenz makes sense, as the drug is prescribed by the same the physicians that prescribe its Abstral drug. The firm views the move as in keeping with Galena's strategy to acquire late-stage drugs that add near-term cash flow to cover some of NeuVax's R&D expenses and it keeps its Overweight rating and $6 target on the stock.
Galena receives notice of allowance of improvement patent for NeuVax in Japan Galena Biopharma announced the notice of allowance from the Japanese Patent Office for NeuVax covering the use of NeuVax alone or in combination with other agents to prevent recurrence of any HER2/neu expressing breast cancer tumor having an immunohistochemistry level of 1+ or 2+, or a fluorescence in situ hybridization rating of less than about 2.0. NeuVax is a peptide immunotherapy for the prevention of cancer recurrence and is Galena's lead development agent in multiple ongoing and planned clinical trials. Once issued, the patent will expire in 2027, not including any patent term extensions.